Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Randomized Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HRS-8080 Combined With Dalpiciclib Versus Fulvestrant Combined With Dalpiciclib in Patients With Locally Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
Conditions
Interventions
HRS-8080 Tablet ; Dalpiciclib Isethionate
Fulvestrant injection ;Dalpiciclib Isethionate
Locations
1
China
Chinese PLA General Hospital Fifth Medical Center
Beijing, Beijing Municipality, China
Start Date
March 4, 2026
Primary Completion Date
December 1, 2028
Completion Date
December 1, 2031
Last Updated
March 27, 2026
NCT02926690
NCT06680921
NCT05744687
NCT02514681
NCT03027245
NCT00634088
Lead Sponsor
Shandong Suncadia Medicine Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions